Supporting this, a case reported by Lu and colleagues detailed how a patient with BRAF V600E-mutant NSCLC responded well to a combined chemotherapy and immunotherapy regimen, achieving a PFS of 20 months (26). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.